Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1984 1
1985 3
1986 2
1987 7
1988 3
1989 1
1990 3
1991 9
1992 2
1993 2
1994 1
1995 6
1996 3
1997 5
1998 3
1999 4
2000 6
2001 5
2002 6
2003 7
2004 6
2005 2
2006 2
2007 4
2008 7
2009 6
2010 7
2011 5
2012 5
2013 9
2014 7
2015 10
2016 5
2017 4
2018 4
2019 3
2020 4
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

159 results
Results by year
Filters applied: . Clear all
Page 1
Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity.
Yu X, Chan HTC, Fisher H, Penfold CA, Kim J, Inzhelevskaya T, Mockridge CI, French RR, Duriez PJ, Douglas LR, English V, Verbeek JS, White AL, Tews I, Glennie MJ, Cragg MS. Yu X, et al. Among authors: glennie mj. Cancer Cell. 2020 Jun 8;37(6):850-866.e7. doi: 10.1016/j.ccell.2020.04.013. Epub 2020 May 21. Cancer Cell. 2020. PMID: 32442402 Free PMC article.
Guidelines for the welfare and use of animals in cancer research.
Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA; Committee of the National Cancer Research Institute. Workman P, et al. Among authors: glennie mj. Br J Cancer. 2010 May 25;102(11):1555-77. doi: 10.1038/sj.bjc.6605642. Br J Cancer. 2010. PMID: 20502460 Free PMC article.
Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8Ā T Cell Effector Function.
Buchan SL, Dou L, Remer M, Booth SG, Dunn SN, Lai C, Semmrich M, Teige I, MƄrtensson L, Penfold CA, Chan HTC, Willoughby JE, Mockridge CI, Dahal LN, Cleary KLS, James S, Rogel A, Kannisto P, Jernetz M, Williams EL, Healy E, Verbeek JS, Johnson PWM, FrendƩus B, Cragg MS, Glennie MJ, Gray JC, Al-Shamkhani A, Beers SA. Buchan SL, et al. Among authors: glennie mj. Immunity. 2018 Nov 20;49(5):958-970.e7. doi: 10.1016/j.immuni.2018.09.014. Epub 2018 Nov 13. Immunity. 2018. PMID: 30446386 Free article.
LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation.
Yeboah M, Papagregoriou C, Jones DC, Chan HTC, Hu G, McPartlan JS, Schiƶtt T, Mattson U, Mockridge CI, Tornberg UC, Hambe B, Ljungars A, Mattsson M, Tews I, Glennie MJ, Thirdborough SM, Trowsdale J, Frendeus B, Chen J, Cragg MS, Roghanian A. Yeboah M, et al. Among authors: glennie mj. JCI Insight. 2020 Sep 1;5(18):e141593. doi: 10.1172/jci.insight.141593. JCI Insight. 2020. PMID: 32870822 Free PMC article.
Rituximab: mechanisms and applications.
Johnson PW, Glennie MJ. Johnson PW, et al. Among authors: glennie mj. Br J Cancer. 2001 Nov 30;85(11):1619-23. doi: 10.1054/bjoc.2001.2127. Br J Cancer. 2001. PMID: 11742477 Free PMC article. Review. No abstract available.
Domain binding and isotype dictate the activity of anti-human OX40 antibodies.
Griffiths J, Hussain K, Smith HL, Sanders T, Cox KL, Semmrich M, MĆ„rtensson L, Kim J, Inzhelevskaya T, Penfold CA, Tutt AL, Mockridge CI, Chan HC, English V, French RF, Teige I, Al-Shamkhani A, Glennie MJ, Frendeus BL, Willoughby JE, Cragg MS. Griffiths J, et al. Among authors: glennie mj. J Immunother Cancer. 2020 Dec;8(2):e001557. doi: 10.1136/jitc-2020-001557. J Immunother Cancer. 2020. PMID: 33428585 Free PMC article.
FcĪ³RĪ™Ī™B controls the potency of agonistic anti-TNFR mAbs.
White AL, Chan HT, French RR, Beers SA, Cragg MS, Johnson PW, Glennie MJ. White AL, et al. Among authors: glennie mj. Cancer Immunol Immunother. 2013 May;62(5):941-8. doi: 10.1007/s00262-013-1398-6. Epub 2013 Mar 31. Cancer Immunol Immunother. 2013. PMID: 23543215 Review.
159 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page